Who Owns Lyell Immunopharma Stock?
NASDAQ: LYELHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 49.27%
- Held by insiders
- 28.62%
- Institutional holders
- 144
- Institutions 49.3%
- Insiders 28.6%
- Public and other 22.1%
Who owns Lyell Immunopharma stock?
Institutional investors own about 49.3% of Lyell Immunopharma's shares, spread across 144 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 28.62% of LYEL.
The largest institutional holders are Arch Venture Management, Llc (10.14%), GSK plc (4.72%) and Blackrock Inc. (2.50%). Together, the top 10 institutions control 29.3% of shares outstanding. In their latest filings, 3 of the top 10 institutions increased their LYEL positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of LYEL
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Arch Venture Management, Llc | 3.25M | 10.14% | 0.0% |
| GSK plc | 1.51M | 4.72% | 0.0% |
| Blackrock Inc. | 799.06K | 2.50% | +10.3% |
| Orland Properties Ltd. | 754.70K | 2.36% | 0.0% |
| Vanguard Capital Management LLC | 748.85K | 2.34% | -4.8% |
| Decheng Capital LLC | 692.05K | 2.16% | 0.0% |
| Almitas Capital LLC | 581.41K | 1.82% | +0.6% |
| Millennium Management Llc | 367.47K | 1.15% | -19.9% |
| AQR Capital Management, LLC | 345.92K | 1.08% | +100.0% |
| venBio Partners LLC | 337.70K | 1.05% | 0.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of LYEL
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 604.46K | 1.89% |
| iShares Trust-iShares Russell 2000 ETF | 228.11K | 0.71% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 163.75K | 0.51% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 107.31K | 0.34% |
| iShares Trust-iShares Russell 2000 Value ETF | 76.88K | 0.24% |
| SCHWAB STRATEGIC TRUST-Schwab U.S. Small-Cap ETF | 66.83K | 0.21% |
| iShares Trust-iShares Biotechnology ETF | 59.77K | 0.19% |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 54.00K | 0.17% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 51.43K | 0.16% |
| VANGUARD WORLD FUND-Vanguard Health Care Index Fund | 28.49K | 0.09% |
Frequently asked questions
Who is the largest shareholder of Lyell Immunopharma?
Arch Venture Management, Llc is the largest institutional shareholder of LYEL, owning 10.14% of shares outstanding (3.25M shares) as of its latest 13F filing.
What percentage of Lyell Immunopharma is owned by institutions?
Institutions own about 49.3% of LYEL shares and 69.0% of the public float.
How much of Lyell Immunopharma do insiders own?
Insiders, such as officers and directors, own about 28.62% of LYEL shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.